Skip to content
Screener

Pre-Tax Income at other companies

Eli Lilly logo
Eli LillyLLY
$9.25B+36.4%
Pfizer logo
PfizerPFE
-$653M-121%
Arrowhead Research logo
Arrowhead ResearchARWR
-$137.57M-137%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$79.47M+1,125%
ALN
Alnylam PharmaceuticalsALNY
$177.81M+603%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$91M+20.2%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.01B+38.9%
Enterprise value$8.92B+27.7%
P/S10.3×+3.4×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000874015-26-000251
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Interest expense related to sale of future royalties(17,506)(18,648)(34,843)(37,470)
Gain (loss) on investments, net(10,182)(18,312)12,401(20,476)
Other income, net987102529569
Income (loss) before income tax benefit (expense)(113,382)123,531(205,692)(23,291)
Income tax benefit (expense)(1,264)20(1,482)(96)
Net income (loss)$$(114,646)$123,551$(207,174)(23,387)
Basic net income (loss) per share$$(0.69)$0.78$(1.25)(0.15)
Diluted net income (loss) per share$$(0.69)$0.70$(1.25)(0.15)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ionis Pharmaceuticals's pre-tax income?
Ionis Pharmaceuticals (IONS) reported pre-tax income of -$113.38M in Q2 2026.
How has Ionis Pharmaceuticals's pre-tax income changed year-over-year?
Ionis Pharmaceuticals's pre-tax income decreased by 191.8% year-over-year, from $123.53M to -$113.38M.
What is the long-term trend for Ionis Pharmaceuticals's pre-tax income?
Over 3 years (2022 to 2025), Ionis Pharmaceuticals's pre-tax income has grown at a 13.7% compound annual growth rate (CAGR), from -$257.99M to -$379.6M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Ionis Pharmaceuticals's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude